The Adjuvant Discovery Program supports the early stage discovery and initial characterization of novel adjuvant candidates for vaccines. The research must include (1) identification of novel adjuvant candidates through high throughput screening (HTS) approaches and validation that lead compounds stimulate human cells; (2) determination of the mechanism of action of select lead compounds, including the identification of the receptor(s) the adjuvant candidates work through and the cellular signaling pathways they activate; (3) optimization of lead adjuvant candidates through formulation and medicinal chemistry, guided by structure-activity relationship (SAR) studies; and (4) verification of the efficacy of lead compounds as vaccine adjuvants in vivo in an animal model. Projects must include animal model studies to test the adjuvant candidates with vaccines against: A) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens www.niaid.nih.gov/topics/emerging/pages/default.aspx), or B) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens as well as one or more other (non-HIV) pathogens relevant to human disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
272201400053C-P00012-9999-1
Application #
10018591
Study Section
Project Start
2014-09-30
Project End
2021-09-29
Budget Start
Budget End
Support Year
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Vaxine Pty Ltd
Department
Type
DUNS #
750421575
City
Bedford Park
State
Country
Australia
Zip Code
5042